正清风痛宁三联序贯疗法联合依那西普治疗强直性脊柱炎的临床效果OA
Clinical efficacy of Zhengqing Fengtongning triple sequential therapy combined with Etanercept in the treatment of ankylosing spondylitis
目的 探讨正清风痛宁三联序贯疗法联合依那西普治疗强直性脊柱炎(AS)的临床效果.方法 回顾性收集2022年1月—2024年12月玉林市中医医院收治的96例AS患者的临床资料,按照治疗方法不同分为对照组(n=48)、联合组(n=48),两组均给予基础治疗,对照组给予依那西普,联合组给予正清风痛宁三联序贯疗法联合依那西普,均治疗12周.比较两组治疗效果、治疗前后病情改善情况[疼痛视觉模拟评分法(VAS)、Bath强直性脊柱炎功能指数(BASFI)、Bath强直性脊柱炎活动性指数(BASDAI)、Bath强直性脊柱炎计量指数(BASMI)]、炎症指标[红细胞沉降率(ESR)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]、疼痛介质[P物质(SP)、前列腺素E2(PGE2)、5-羟色胺(5-HT)]、免疫功能(IgA、IgG、IgM)及不良反应.结果 与对照组的77.08%(37/48)比较,联合组总有效率93.75%(45/48)显著升高(P<0.05).与对照组比较,治疗12周后联合组BASFI、BASDAI、BASMI及疼痛VAS评分均降低(P<0.05);与对照组比较,治疗12周后联合组血清CRP、TNF-α、SP、PGE2、5-HT、IgA、IgG、IgM水平以及ESR均降低(P<0.05).两组不良反应总发生率差异无统计学意义(P>0.05).结论 正清风痛宁三联序贯疗法联合依那西普可显著提高AS治疗效果,有效改善患者临床症状和功能状态,降低炎症指标及疼痛介质水平,调节免疫功能,且安全性良好.
Objective To investigate the clinical efficacy of Zhengqing Fengtongning triple sequential therapy combined with Etanercept in the treatment of ankylosing spondylitis(AS).Methods The clinical data of 96 AS patients admitted to Yulin Hospital of Traditional Chinese Medicine from January 2022 to December 2024 were retrospectively collected.According to different treatment methods,they were divided into the control group(n=48)and the combination group(n=48).Both groups were given basic treatment.The control group was given Etanercept,while the combination group was given Zhengqing Fengtongning sequential therapy combined with Etanercept.Both groups were treated for 12 weeks.The therapeutic effects,improvement of conditions before and after treatment[visual analogue scale(VAS)for pain,Bath Ankylosing Spondylitis Functional Index(BASFI),Bath Ankylosing Spondylitis Active Index(BASDAI),Bath Ankylosing Spondylitis Metrology Index(BASMI)],inflammatory indicators[erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)],pain mediators[substance P(SP),prostaglandin E2(PGE2),5-hydroxytryptamine(5-HT)],immune function(IgA,IgG,IgM)and adverse reactions were compared between the two groups.Results Compared with the 77.08%(37/48)in the control group,the total effective rate of the combination group was significantly higher at 93.75%(45/48)(P<0.05).Compared with the control group,at 12 weeks after treatment,the BASFI,BASDAI,BASMI and VAS pain scores of the combination group all decreased(P<0.05).Compared with the control group,the serum CRP,TNF-α,SP,PGE2,5-HT,IgA,IgG,IgM levels and ESR of the combination group all decreased(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Zhengqing Fengtongning triple sequential therapy combined with Etanercept can significantly improve the therapeutic effect of AS,effectively alleviate the clinical symptoms and functional status of patients,reduce inflammatory indicators and pain mediators levels,regulate immune function,and has good safety.
许小香;庞学丰;陈甲秀;陈健;顾崎峰;臧海珍;伍彦洁
广西中医药大学第二附属医院风湿免疫科,南宁 530000||玉林市中医医院风湿病科,广西壮族自治区 玉林 537000广西中医药大学第二附属医院风湿免疫科,南宁 530000玉林市中医医院风湿病科,广西壮族自治区 玉林 537000玉林市中医医院风湿病科,广西壮族自治区 玉林 537000玉林市中医医院风湿病科,广西壮族自治区 玉林 537000玉林市中医医院风湿病科,广西壮族自治区 玉林 537000玉林市中医医院风湿病科,广西壮族自治区 玉林 537000
强直性脊柱炎正清风痛宁序贯疗法依那西普炎症因子疼痛介质免疫功能
ankylosing spondylitisZhengqing Fengtongningsequential therapyEtanerceptinflammatory factorspain mediatorsimmune function
《临床误诊误治》 2026 (13)
79-85,7
广西名中医传承工作室建设项目(GZY2024020)玉林市科学研究与技术开发计划项目(玉市科202432085)
评论